July 2024
Montara Therapeutics Launches with $8M to Develop Safer Neurological Therapeutics
Montara Therapeutics, neurological therapeutics, BrainOnly platform, seed funding, safer treatments
Merck & Co.’s Keytruda Achieves $7 Billion in Quarterly Sales, Surpassing Expectations
Merck & Co., Keytruda, quarterly sales, Winrevair, pharmaceuticals, oncology
Pinetree Therapeutics Secures $17M in Funding to Advance Targeted Protein Degraders
Pinetree Therapeutics, targeted protein degraders, TPD, Series A funding, pharmaceutical development
BioNTech and Regeneron Achieve Positive Phase II Results for mRNA Cancer Vaccine Combo in Melanoma
BioNTech, Regeneron, mRNA cancer vaccine, melanoma, Phase II trial, Libtayo, cemiplimab, BNT111, immunotherapy
China’s Corruption Crackdown Impacts Merck’s Gardasil Sales, Rattling Investors
Merck, Gardasil, China, Corruption Crackdown, Healthcare, Pharmaceuticals, HPV Vaccine
Incyte Reports Positive Results for PD-1 Inhibitor Zynyz in Two Phase 3 Clinical Trials
Incyte, Zynyz, PD-1 Inhibitor, Phase 3 Clinical Trials, Squamous Cell Anal Carcinoma, Non-Small Cell Lung Cancer
BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111
BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology
WuXi AppTec Faces Revenue Decline Amid Looming BIOSECURE Act Threat
WuXi AppTec, BIOSECURE Act, Revenue Decline, Biotechnology, US-China Relations
Celldexs anti-cKIT antibody proves it can reduce chronic hives in another phase 2 trial
Antibodies, Trial Phase, Urticaria, chronic hives
Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease
Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure